STAT's podcast The Readout Loud discusses Summit's cancer immunotherapy, the company's co-CEO, Moderna's spending cuts and ...

Merck & Co has followed the lead of other big pharma groups like Pfizer and GlaxoSmithKline by hiving off its mature and off-patent drugs into a new company. The decision will take some 90 ...

Merck’s MRK stock has declined around 10.3% in the past three months, losing almost $32 billion of its market value. Merck ...

Merck (MRK) and Daiichi Sankyo's (DSNKY) lung cancer drug, patritumab deruxtecan hits the primary endpoint in a Phase 3 trial ...

Merck ( MRK 0.53%) stock has been a longtime winner for investors, returning 72% in the past five years. A major factor in ...

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

Merck's combination of a wide lineup of high-margin drugs and a pipeline of new drugs should ensure strong returns on invested capital over the long term. Further, following the divestment of the ...

The disease is proving very difficult for pharma to tackle, and Merck’s decision casts doubt on the class of drugs known as beta-site amyloid precursor protein cleaving enzyme 1 (BACE1 ...

Merck said Thursday that it would lower the price of some of its medications including its hepatitis C drug Zepatier by 60%. The decision comes a little over a week after President Donald J.

The Institute of Cancer Research and science and technology company Merck KGaA have renewed their strategic alliance in the discovery and development of new cancer drugs. Scientists in the Centre for ...

Merck Serono, the biopharmaceutical division of Merck, The Institute of Cancer Research (ICR), and the Wellcome Trust, London, today announced a co-development and license agreement building on two ...

Future Market Insights (FMI), a leading authority in pharmaceutical industry analysis, is strategically positioning itself to ...